Jefferies Issues an Upgrade on Sanofi (SNY) Shares. What’s Next?

Sanofi (NYSE:SNY) Logo

Sanofi (SNY) Stock Upgrade

In a note revealed on Tuesday, 11 December, investment analysts at the Jefferies equity research division upgraded shares of Sanofi (SNY) stock from a “Hold” to a respectable “Buy” rating.

The stock increased 0.34% or $0.15 during the last trading session, reaching $44.32. About 1.34M shares traded or 4.00% up from the average. Sanofi (SNY) has risen 2.03% since December 12, 2017 and is uptrending. It has outperformed by 2.03% the S&P500.

Analysts await Sanofi (NYSE:SNY) to report earnings on February, 6. They expect $0.63 earnings per share, up 1.61 % or $0.01 from last year’s $0.62 per share. SNY’s profit will be $1.56B for 17.59 P/E if the $0.63 EPS becomes a reality. After $1.07 actual earnings per share reported by Sanofi for the previous quarter, Wall Street now forecasts -41.12 % negative EPS growth.

Sanofi researches, develops, manufactures, and markets therapeutic solutions. The company has market cap of $109.94 billion. The firm operates in two divisions, Pharmaceuticals and Vaccines. It has a 22.85 P/E ratio. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an oral immunomodulatory and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

More notable recent Sanofi (NYSE:SNY) news were published by: Fool.com which released: “3 Top Biotech Stocks to Buy in December – Motley Fool” on December 11, 2018, also Streetinsider.com with their article: “Jefferies Upgrades Sanofi (SAN:FP) (SNY) to Buy – StreetInsider.com” published on December 11, 2018, Investorplace.com published: “5 Biotech Stocks to Scoop Up for Big Dividends – Investorplace.com” on November 27, 2018. More interesting news about Sanofi (NYSE:SNY) were released by: Seekingalpha.com and their article: “MyoKardia down 1% premarket on early-stage MYK-491 data – Seeking Alpha” published on December 11, 2018 as well as Bizjournals.com‘s news article titled: “Shire-Takeda deal gets conditional EU approval, heads to shareholders – Boston Business Journal” with publication date: November 20, 2018.

Sanofi (NYSE:SNY) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.